Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labeling
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 1, 2004
April 27, 2020
08e99d11-48f5-4d96-a72c-c66cde9d04ca
Related Documents
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
Guidance DocumentMarch 18, 2014Center for Drug Evaluation and Research
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs
Guidance DocumentOctober 21, 2022Center for Drug Evaluation and Research
Public Availability of Labeling Changes in "Changes Being Effected" Supplements
Guidance DocumentSeptember 20, 2006Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox